Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: Sadif Analytics Prime
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Summit Corporation plc announces FDA grants QIDP designation to summit's novel antibiotic for treatment of C. difficile Infection


Wednesday, 9 Jul 2014 02:00am EDT 

Summit Corporation plc:US Food and Drug Administration (FDA) has designated co's novel antibiotic SMT19969 for treatment of CDI as qualified infectious disease product.QIDP designation allows summit to benefit from number of incentives supporting development of new antibiotics including eligibility for priority review and fast track status and, if SMT19969 receives marketing approval from FDA, five-year extension of market exclusivity. 

Company Quote

116.0
-5.5 -4.53%
23 Jan 2015